Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis reportPriya S. Kishnani, Yin‐Hsiu Chien, David Kronn et al.|Genetics in Medicine|2022Cited by 53
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective studySi Houn Hahn, Priya S. Kishnani, David Kronn et al.|Genetics in Medicine|2018Cited by 31
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe diseasePriya S. Kishnani, Si Houn Hahn, Richard E. Hillman et al.|Genetics in Medicine|2019Cited by 16
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohortBarry J. Byrne, Raymond Wang, Steven D. Colan et al.|Cardiology in the Young|2021Cited by 15
OP016: Mini-COMET: Safety and efficacy of ≥97 weeks’ avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfaDavid Kronn, On behalf of the Mini-COMET investigators, James Davison et al.|Genetics in Medicine|2022Cited by 10